FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310258547> ?p ?o ?g. }

• W4310258547 endingPage "2563" @default.
• W4310258547 startingPage "2552" @default.
• W4310258547 abstract "MGB-BP-3 is a potential first-in-class antibiotic, a Strathclyde Minor Groove Binder (S-MGB), that has successfully completed Phase IIa clinical trials for the treatment of Clostridioides difficile associated disease. Its precise mechanism of action and the origin of limited activity against Gram-negative pathogens are relatively unknown. Herein, treatment with MGB-BP-3 alone significantly inhibited the bacterial growth of the Gram-positive, but not Gram-negative, bacteria as expected. Synergy assays revealed that inefficient intracellular accumulation, through both permeation and efflux, is the likely reason for lack of Gram-negative activity. MGB-BP-3 has strong interactions with its intracellular target, DNA, in both Gram-negative and Gram-positive bacteria, revealed through ultraviolet-visible (UV-vis) thermal melting and fluorescence intercalator displacement assays. MGB-BP-3 was confirmed to bind to dsDNA as a dimer using nano-electrospray ionization mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy. Type II bacterial topoisomerase inhibition assays revealed that MGB-BP-3 was able to interfere with the supercoiling action of gyrase and the relaxation and decatenation actions of topoisomerase IV of both Staphylococcus aureus and Escherichia coli. However, no evidence of stabilization of the cleavage complexes was observed, such as for fluoroquinolones, confirmed by a lack of induction of DSBs and the SOS response in E. coli reporter strains. These results highlight additional mechanisms of action of MGB-BP-3, including interference of the action of type II bacterial topoisomerases. While MGB-BP-3's lack of Gram-negative activity was confirmed, and an understanding of this presented, the recognition that MGB-BP-3 can target DNA of Gram-negative organisms will enable further iterations of design to achieve a Gram-negative active S-MGB." @default.
• W4310258547 created "2022-11-30" @default.
• W4310258547 creator A5010095671 @default.
• W4310258547 creator A5012805006 @default.
• W4310258547 creator A5016484620 @default.
• W4310258547 creator A5018182814 @default.
• W4310258547 creator A5023144025 @default.
• W4310258547 creator A5025023736 @default.
• W4310258547 creator A5048192920 @default.
• W4310258547 creator A5061640601 @default.
• W4310258547 creator A5062758536 @default.
• W4310258547 creator A5071455462 @default.
• W4310258547 creator A5076071353 @default.
• W4310258547 creator A5076835719 @default.
• W4310258547 creator A5084402711 @default.
• W4310258547 creator A5084930078 @default.
• W4310258547 creator A5088303429 @default.
• W4310258547 date "2022-11-29" @default.
• W4310258547 modified "2023-10-14" @default.
• W4310258547 title "Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP-3" @default.
• W4310258547 cites W1559330249 @default.
• W4310258547 cites W1985550031 @default.
• W4310258547 cites W2016562927 @default.
• W4310258547 cites W2018996043 @default.
• W4310258547 cites W2031888031 @default.
• W4310258547 cites W2034401300 @default.
• W4310258547 cites W2072980542 @default.
• W4310258547 cites W2111967267 @default.
• W4310258547 cites W2112903691 @default.
• W4310258547 cites W2125499673 @default.
• W4310258547 cites W2136332525 @default.
• W4310258547 cites W2315474490 @default.
• W4310258547 cites W2377543751 @default.
• W4310258547 cites W2433057126 @default.
• W4310258547 cites W2615150832 @default.
• W4310258547 cites W2749087629 @default.
• W4310258547 cites W2913745046 @default.
• W4310258547 cites W2956943766 @default.
• W4310258547 cites W3033036388 @default.
• W4310258547 cites W3120600373 @default.
• W4310258547 cites W3182580572 @default.
• W4310258547 cites W4205381788 @default.
• W4310258547 cites W4206504757 @default.
• W4310258547 cites W4210626045 @default.
• W4310258547 cites W4229008873 @default.
• W4310258547 cites W4229050629 @default.
• W4310258547 doi "https://doi.org/10.1021/acsinfecdis.2c00445" @default.
• W4310258547 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36444998" @default.
• W4310258547 hasPublicationYear "2022" @default.
• W4310258547 type Work @default.
• W4310258547 citedByCount "5" @default.
• W4310258547 countsByYear W43102585472023 @default.
• W4310258547 crossrefType "journal-article" @default.
• W4310258547 hasAuthorship W4310258547A5010095671 @default.
• W4310258547 hasAuthorship W4310258547A5012805006 @default.
• W4310258547 hasAuthorship W4310258547A5016484620 @default.
• W4310258547 hasAuthorship W4310258547A5018182814 @default.
• W4310258547 hasAuthorship W4310258547A5023144025 @default.
• W4310258547 hasAuthorship W4310258547A5025023736 @default.
• W4310258547 hasAuthorship W4310258547A5048192920 @default.
• W4310258547 hasAuthorship W4310258547A5061640601 @default.
• W4310258547 hasAuthorship W4310258547A5062758536 @default.
• W4310258547 hasAuthorship W4310258547A5071455462 @default.
• W4310258547 hasAuthorship W4310258547A5076071353 @default.
• W4310258547 hasAuthorship W4310258547A5076835719 @default.
• W4310258547 hasAuthorship W4310258547A5084402711 @default.
• W4310258547 hasAuthorship W4310258547A5084930078 @default.
• W4310258547 hasAuthorship W4310258547A5088303429 @default.
• W4310258547 hasBestOaLocation W43102585471 @default.
• W4310258547 hasConcept C104317684 @default.
• W4310258547 hasConcept C12554922 @default.
• W4310258547 hasConcept C147897179 @default.
• W4310258547 hasConcept C158456008 @default.
• W4310258547 hasConcept C167125095 @default.
• W4310258547 hasConcept C185592680 @default.
• W4310258547 hasConcept C202751555 @default.
• W4310258547 hasConcept C2776120743 @default.
• W4310258547 hasConcept C547475151 @default.
• W4310258547 hasConcept C552990157 @default.
• W4310258547 hasConcept C55493867 @default.
• W4310258547 hasConcept C73573662 @default.
• W4310258547 hasConcept C86803240 @default.
• W4310258547 hasConceptScore W4310258547C104317684 @default.
• W4310258547 hasConceptScore W4310258547C12554922 @default.
• W4310258547 hasConceptScore W4310258547C147897179 @default.
• W4310258547 hasConceptScore W4310258547C158456008 @default.
• W4310258547 hasConceptScore W4310258547C167125095 @default.
• W4310258547 hasConceptScore W4310258547C185592680 @default.
• W4310258547 hasConceptScore W4310258547C202751555 @default.
• W4310258547 hasConceptScore W4310258547C2776120743 @default.
• W4310258547 hasConceptScore W4310258547C547475151 @default.
• W4310258547 hasConceptScore W4310258547C552990157 @default.
• W4310258547 hasConceptScore W4310258547C55493867 @default.
• W4310258547 hasConceptScore W4310258547C73573662 @default.
• W4310258547 hasConceptScore W4310258547C86803240 @default.
• W4310258547 hasFunder F4320307874 @default.
• W4310258547 hasFunder F4320314731 @default.
• W4310258547 hasFunder F4320320176 @default.

• next